Cluster-Randomized Test-Negative Design Trials: A Novel and Efficient Method to Assess the Efficacy of Community-Level Dengue Interventions. by Anders, Katherine L et al.
Anders, KL; Cutcher, Z; Kleinschmidt, I; Donnelly, CA; Ferguson,
NM; Indriani, C; O’Neill, SL; Jewell, NP; Simmons, CP (2018) Clus-
ter Randomized Test-Negative Design (CR-TND) Trials: A Novel
and Efficient Method to Assess the Efficacy of Community Level
Dengue Interventions. American journal of epidemiology. ISSN 0002-
9262 DOI: https://doi.org/10.1093/aje/kwy099
Downloaded from: http://researchonline.lshtm.ac.uk/4647718/
DOI: 10.1093/aje/kwy099
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
  
 
1 
Cluster Randomized Test-Negative Design (CR-TND) Trials: A Novel and Efficient Method 
to Assess the Efficacy of Community Level Dengue Interventions 
Katherine L. Anders#, Zoe Cutcher#, Immo Kleinschmidt, Christl A. Donnelly, Neil M. 
Ferguson, Citra Indriani, Scott L. O’Neill, Nicholas P. Jewell, and Cameron P. Simmons 
# These authors contributed equally to this work 
Correspondence to: Dr. Katherine Anders, Institute of Vector-Borne Disease, Monash 
University, 12 Innovation Walk, Clayton 3800, Victoria, Australia (tel: +61 3 9905 2713; e-
mail: katie.anders@worldmosquito.org)  
Author affiliations: Institute of Vector-Borne Disease, Monash University, Melbourne, 
Australia (Katherine L. Anders, Zoe Cutcher, Scott L. O’Neill, Cameron P. Simmons); MRC 
Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London 
School of Hygiene and Tropical Medicine, London, UK, and School of Pathology, Faculty of 
Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (Immo 
Kleinschmidt); Medical Research Council Centre for Outbreak Analysis and Modelling, 
Department of Infectious Disease Epidemiology, School of Public Health, Imperial College 
London, London, UK (Christl A. Donnelly, Neil M. Ferguson); Department of Biostatistics, 
Epidemiology and Population Health, Centre for Tropical Medicine, Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta, Indonesia (Citra Indriani); School of Public Health, 
University of California, Berkeley, California (Nicholas P. Jewell). 
Funding: This work was supported by the Bill and Melinda Gates Foundation and the 
Wellcome Trust. 
Conflict of interest: The authors declare they have no conflict of interest. 
Running head: Cluster Randomized Test-Negative Design Trials 
  
© The Author(s) 2018. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public 
Health. This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted reuse, distribution, and reproduction in any 
medium, provided the original work is properly cited. 
Downloaded from https://academic.oup.com/aje/advance-article-abstract/doi/10.1093/aje/kwy099/4993480
by London School of Hygiene & Tropical Medicine user
on 15 May 2018
  
 
2 
ABSTRACT 
Cluster randomized trials are the gold standard for assessing efficacy of community-level 
interventions, such as vector control strategies against dengue. We describe a novel cluster 
randomized trial methodology with a test-negative design, which offers advantages over 
traditional approaches. It utilizes outcome-based sampling of patients presenting with a 
syndrome consistent with the disease of interest, who are subsequently classified as test-
positive cases or test-negative controls on the basis of diagnostic testing. We use 
simulations of a cluster trial to demonstrate validity of efficacy estimates under the test-
negative approach. This demonstrates that, provided study arms are balanced for both test-
negative and test-positive illness at baseline and that other test-negative design 
assumptions are met, the efficacy estimates closely match true efficacy. We also briefly 
discuss analytical considerations for an odds ratio-based effect estimate arising from 
clustered data, and outline potential approaches to analysis. We conclude that application 
of the test-negative design to certain cluster randomized trials could increase their 
efficiency and ease of implementation. 
KEY WORDS 
Case control; cluster randomized trial; dengue; efficacy; odds ratio; study design; test-
negative design; Wolbachia. 
ABBREVIATIONS 
CRT: Cluster randomized controlled trial; CR-TND: Cluster randomized trial with test-
negative design sampling; TND: Test-negative design  
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Cluster randomized controlled trials (CRTs) are the gold standard for evaluating the efficacy 
of health interventions delivered at the community level, including vector control 
interventions to reduce transmission of arboviruses such as dengue and Zika. A recent 
literature review emphasized the need for quality randomized controlled trials to improve 
disease control strategies (1, 2). The importance of measuring impact on disease, not only 
on vector indices, has been specifically highlighted. However, it is widely accepted that trials 
using clinical endpoints can be resource intensive and logistically difficult to implement. 
CRTs customarily randomly allocate an intervention to some predefined spatial units, and 
follow a cohort of ‘at risk’ participants over time to measure the endpoint of interest in 
treated versus untreated clusters. When sufficient units are available, randomization results 
in groups comparable in all factors except for the intervention under study, and provides the 
basis for statistical inference (3). Such trials with epidemiological endpoints are resource 
intensive due to the requirement for active case surveillance. The non-independence of 
individuals within each cluster and resultant statistical inefficiency necessitates inflation of 
the CRT sample size to achieve power equivalent to an individually randomized trial (3-6). 
Traditional CRTs frequently require thousands of participants to generate sufficient events 
for hypothesis testing (7-12) particularly for interventions against uncommon events, e.g. 
clinically apparent dengue. This has significant cost, time, ethical and logistical implications. 
These challenges may partly account for the small number of cluster randomized controlled 
trials and subsequent weak evidence base for vector-control interventions against 
arboviruses (1), limiting evidence-based decision making for disease control. 
Considerable literature demonstrates that sampling participants on the basis of their 
outcome status (case-control design) rather than their exposure status (cohort design) 
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increases efficiency of observational studies (13-17). We propose a CRT study design with 
test-negative sampling (CR-TND), a form of outcome-based recruitment, as an efficient 
method to assess the efficacy of community-level interventions against dengue (such as 
introgression of Wolbachia into mosquito populations (18, 19)). The approach offers the 
advantage of being more efficient, cost-effective, and logistically simpler to achieve than a 
traditional CRT.  We review the assumptions inherent to the test-negative design (TND) and 
how these relate to its application in the context of a cluster randomized trial, use 
simulations to demonstrate the validity of estimates produced by a CR-TND study, and 
discuss potential approaches to analysis and interpretation of results. 
 
ASSUMPTIONS OF THE TEST-NEGATIVE DESIGN AND APPLICATION TO CRTs 
The TND is a modified case-cohort study in which symptomatic patients meeting pre-
defined inclusion/exclusion criteria are enrolled and subsequently classified as test-positive 
‘cases’ or test-negative ‘controls’ based on the results of definitive diagnostic testing. This 
design is frequently used for evaluating the effectiveness of seasonal influenza vaccination  
(20-25) and its internal validity has been explored in depth (20-23, 26-28). Briefly, validity 
depends primarily upon the avoidance of selection bias in the sampling of cases and 
controls, and the extent to which the exposure distribution amongst controls is 
representative of the exposure distribution amongst the source population that gives rise to 
cases. Key assumptions and their relevance to CR-TND trials are discussed below. For ease 
of discussion we refer to the illness in those testing positive for the pathogen of interest as 
“test-positive illness”, and in those testing negative as “test-negative illness”. 
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Assumption 1. Test-negative illness is not associated with the intervention  
A core assumption of the TND is that the test-negative illness is not affected by the 
intervention (21, 22, 26); i.e. in the case of influenza VE studies, receipt of the influenza 
vaccine would not be expected to modify the incidence of non-influenza ARI. In randomized 
trials, random allocation of the intervention reduces the likelihood of any association 
between test-negative illness and the intervention. With an increasing number of clusters, 
the likelihood of test-negative illness occurring disproportionately in one study arm by 
chance is reduced. This may be particularly relevant where the test-negative illness is a 
communicable disease, as these tend to cluster in space and time. In cluster randomized 
trials with few allocation units, constrained randomization (29) can improve balance in 
factors potentially associated with test-positive or test-negative illness. Randomization thus 
represents a methodological advantage over influenza vaccine effectiveness studies in 
which self-selection may lead to an association between the intervention and outcome.  
Assumption 2. Non-differential probability of seeking health care 
Haber et al. (26) suggested the TND yields an unbiased estimate of effectiveness/efficacy 
even if the likelihood of seeking healthcare (and being enrolled) is associated with the 
intervention, provided this association exists for both test-positive and test-negative 
patients (26). Thus the TND may reduce bias due to intervention-driven changes to 
healthcare-seeking behavior relative to traditional cohort designs, a feature that may be 
particularly appealing in cluster randomized trials if blinding the community to intervention 
status is not feasible. A recent exploration of the theoretical basis of the TND in 
observational studies of influenza vaccine effectiveness (28) argued that the TND achieves a 
reduction in, rather than elimination of, bias due to healthcare-seeking behavior, since 
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healthcare-seeking behavior represents a continuous propensity rather than a simple binary 
variable that can be conditioned upon. Such potential bias should be further reduced in the 
CR-TND, since randomization of the intervention should achieve balance between study 
arms in individuals’ average propensity to seek healthcare. Constrained randomization can 
further enforce a balance between study arms in their baseline observed incidence of test-
negative illness (that incorporates care-seeking propensity as well as true disease 
incidence).  
Assumption 3.  The efficacy of the intervention is not associated with healthcare-seeking 
behavior 
The external validity of the TND depends on the intervention being equally effective across 
groups with different healthcare-seeking behavior, such that the effectiveness/efficacy 
estimate generated through a study of individuals presenting to clinics is generalizable to 
the broader population (21). A limitation to this assumption could arise in both TND and CR-
TND studies if those more or less likely to seek care at a study clinic differ systematically in 
some factor associated with intervention effectiveness. For example, if socioeconomic 
status differs with healthcare-seeking behavior, this may correlate with differences in 
housing, vector density, community uptake of the intervention, or other factors that might 
impact the effectiveness of a dengue vector control intervention.  Tacitly, in extending 
effectiveness estimates to cases of all severity, we assume that the intervention does not 
modify the spectrum of disease outcomes. 
Assumption 4. The test used to determine disease status is highly sensitive and specific. 
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Several authors (23, 26, 30) have modeled the effects of imperfect diagnostic testing on the 
TND estimate under different scenarios, demonstrating that a test (or combination of tests) 
with imperfect sensitivity or specificity biases the estimate toward the null, with the 
greatest bias arising from imperfect specificity. This, of course, remains true with clustered 
participants since clustering affects variation and not bias. Thus TND or CR-TND studies that 
demonstrate effectiveness/efficacy even with imperfect test sensitivity and/or specificity 
will underestimate the true effect (23). Use of a consistent diagnostic algorithm, gold 
standard diagnostic tests, and with laboratory testing performed blind to exposure status, 
will minimize the potential for differential or non-differential outcome misclassification to 
bias the estimates from a TND or CR-TND study, in the same way as for other designs. 
Assumption 5. Uncensored sampling of controls 
The effect measure estimated from a retrospective study depends critically upon the criteria 
applied to the selection of controls (31, 32). If controls are drawn from all individuals in the 
population at risk, without exclusion of those who test positive at any other time during the 
study period (i.e. uncensored or inclusive sampling), then the exposure distribution in the 
controls can be assumed to reflect the exposure distribution in the source population. In 
that case the study provides a direct estimate of the population relative risk, without 
dependence on the rare disease assumption (32, 33), and, in this regard, a TND most 
resembles a case-cohort design. If controls are sampled inclusively as above, and also 
longitudinally throughout the study period concurrently with cases (incidence-density or risk-
set sampling), then their cumulative exposure distribution represents that of the source 
population at each point in time (‘risk period’) that a case arose. If this temporal matching is 
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accounted for in the analysis, then the odds ratio directly estimates a population incidence 
rate ratio (31, 33, 34).  
In the case of a (cluster randomized) test-negative design study, patients presenting to 
participating clinics with a test-negative illness are assumed to represent a sample of the 
source population from which cases arise, i.e. the population who would present to these 
clinics and be enrolled as a case if they experienced a test-positive illness. Foppa et al. (25) 
have demonstrated that TND studies using incidence density sampling produce valid 
estimates of effect even when the incidence of test-positive or test-negative illness varies 
temporally. Because calendar time may correlate also with the exposure distribution (e.g. 
influenza vaccination uptake), analyses of observational TND studies have often included 
adjustment for calendar time (21). In the analysis of a CR-TND study, a participant’s 
exposure to the intervention is considered fixed and non-time varying for the purpose of the 
intention-to-treat analysis, as per the randomized allocation, in which case time adjustment 
is not warranted. A per-protocol analysis, however, may account for individuals’ time-
varying exposure to the intervention and require adjustment for calendar time. 
Assumption 6.  Participants with test-negative illness are only recruited when test-positive 
illness is circulating 
An extension of assumption 5 in the case of a seasonal illness is that, in order to achieve 
incidence density sampling of test-positive and test-negative participants, recruitment 
should only occur during periods when test-positive illness is circulating (21). Outside the 
transmission season there is effectively no ‘population at risk’ of test-positive illness, and 
therefore test-negative controls recruited during this period are not a valid sample of the 
source population from which test-positive cases arise. This principle holds also for CR-TND 
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studies. In practice, if a study is to run over more than one transmission season it may be 
infeasible to stop and start patient recruitment, or the beginning and end of the 
transmission periods may not be easily predicted in advance. This criterion can still be met 
while allowing continuous recruitment, by restricting the dataset for analysis to include only 
those test-negative controls enrolled during periods in which there were also test-positive 
participants recruited. 
Finally, we note that many of the concerns regarding the TND raised by careful 
consideration of biases (27, 28, 35) are mitigated, or removed, by exposure randomization 
in a CR-TND. For example, randomization essentially removes the impact of differential 
misclassification of disease outcome within levels of extraneous factors (28) since the latter 
are balanced across arms. In addition, in the case of an infectious disease where spatio-
temporal heterogeneity could lead to differences in baseline risk of illness between clusters, 
randomization of a sufficient number of clusters will ensure the overall risk of illness 
remains balanced between study arms. The causal diagrams relevant to TNDs (specifically 
directed acyclic graphs: DAGs) (28) apply here directly but are simplified as no arrows point 
into the (randomly assigned) intervention node; clustering of response does not affect a 
DAG. Further, randomization of exposure removes bias from estimation of marginal odds 
ratio measures of association (27). The non-collapsibility of the odds ratio (27) applies here 
to the extent that an intervention’s effect at a cluster level may be greater than the 
population effect; however, this means that the latter measure will simply be conservative. 
Later, in the paper we show that basic estimation procedures for CRTs and TNDs can be 
straightforwardly extended to CR-TND study data.  
SIMULATIONS 
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We assessed the validity of efficacy estimates generated through a CR-TND using 
simulations and found accurate and unbiased estimates are produced, provided the 
randomization achieves balance between study arms at baseline in both the outcome of 
interest and the test-negative illness, and other assumptions of the TND are met.  We 
simulated scenarios to compare the CR-TND efficacy estimate against the true efficacy of a 
hypothetical preventive intervention against dengue (Web Figure 1). Initially we assumed 
the intervention had no effect. Hypothetical study populations were generated, consisting 
of 20-100 clusters, each with a random population size drawn from a uniform distribution 
with range 5000 to 25,000. Baseline dengue and test-negative illness incidence rates in each 
cluster were simulated based on independent Beta distributions, and applied to cluster 
population sizes to yield case counts for each category (Web Figure 2). Parameter choices 
for test-negative illness incidence were selected to yield two distinct values of the inter-
cluster coefficient of variation (k), k = 0.5 and 0.25; k was set at 0.5 for dengue incidence. 
The rate parameters were selected to mimic dengue case notification rates (36-38) and k 
values (39) from southeast Asian dengue endemic settings. Note that any co-variation of 
dengue and test-negative case counts arises solely from common cluster population sizes.  
We randomly allocated half the clusters to receive the intervention. We performed simple 
randomization, plus three constrained randomizations in which we generated a large 
number of potential random allocations and accepted only those in which the baseline i) 
dengue incidence, ii) test-negative illness incidence or iii) both dengue and test-negative 
illness incidence were balanced between arms, defined as a difference of ≤10% in aggregate 
incidence. 
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We calculated the exposure odds ratio (OR) in dengue vs test-negative controls for each 
random allocation, using the standard formula:  
OR = 
𝑑𝑒𝑛𝑔𝑢𝑒 𝑐𝑎𝑠𝑒𝑠 𝑖𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚
𝑑𝑒𝑛𝑔𝑢𝑒 𝑐𝑎𝑠𝑒𝑠 𝑖𝑛 𝑛𝑜𝑛−𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚
 / 
𝑡𝑒𝑠𝑡−𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚
𝑡𝑒𝑠𝑡−𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖𝑛 𝑛𝑜𝑛−𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚
 . 
For simplicity, we assumed complete sampling of dengue (test-positive) cases and test-
negative controls from both study arms, perfect diagnostic test sensitivity and specificity, 
and that all assumptions of the TND were met. Thus the only variation across simulations 
was in cluster intervention assignment. We repeated each simulation 1,000 times for each 
combination of the number of clusters and inter-cluster coefficient of variation. The 
percentage deviation from the expected null value (i.e. OR=1) was assessed for each 
simulation (Figure 1). 
Results demonstrate that the odds ratio estimated through a CR-TND study approximates 
the true null value. Random variation around the null is particularly reduced when study 
arms are balanced for both test-positive and test-negative illness baseline incidence. Such 
variation also decreases as the number of study clusters increases and at the lower value of 
inter-cluster heterogeneity for test-negative illness incidence. With balance on historical 
incidence of both dengue and test-negative outcomes, estimation is effective even with 
small numbers of clusters (Figure 1D). 
We further investigated validity of the odds ratio estimates assuming a true intervention 
efficacy of 50%, by repeating the above steps while deterministically halving dengue 
incidence in each intervention cluster. The deviation of the simulation-derived odds ratio 
estimates from the expected ‘true’ value was identical for an assumed efficacy of 50% (Web 
Figure 3) and at the null (Figure 1).   
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ANALYSIS OF CLUSTER RANDOMIZED TEST-NEGATIVE DESIGN STUDIES 
Community-level interventions introduce additional complexity into analysis of a CR-TND 
compared to an observational TND study, while allowing inference to be based on 
randomization. With test-negative designs, vaccine effectiveness is usually estimated 
through the odds ratio as defined above (21).  Logistic regression models allow adjustment 
for potential confounders (20, 40) including calendar time. Common adjustments are time-
matching using a conditional logistic regression model, or inclusion of calendar week as a 
categorical parameter using splines in an unconditional model  (40). For a CR-TND, however, 
any analysis needs to account for the clustering. We note two possible approaches that 
adapt procedures commonly used for CRTs. 
(a) Cluster-level Summary Data: We can simply use the estimated odds ratio based on 
data aggregated across all clusters, with the null hypothesis that the odds of being in the 
intervention arm is the same among test-positives as test-negatives. Inference can be based 
on the permutation distribution that considers all possible cluster intervention assignments. 
An approximate version of this test uses an estimate of the variance of the estimated odds 
ratio that accounts for the clustering using simple finite population sampling ideas (41).  
The aggregate odds ratio provides a consistent estimate of the relative risk, albeit at a 
population-averaged, or marginal, level (41). (This is in contrast to a cluster-specific odds 
ratio that is, in general, further from the null than the marginal version—see (3); the 
difference is not of practical concern with rare outcomes). Confidence intervals can either 
be based on inverting the permutation test or via the approximate variance formula (41).  
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An alternative summary efficacy measure is based on the proportion of test-positive 
patients (amongst all tested individuals) in each cluster. At the null, the average of these 
proportions should be the same in both arms. For testing, the average of these proportions 
for the intervention clusters can then be compared to the same for control clusters via the t-
statistic, with inference based on a permutation test again, or on an approximate variance 
(41).  
This approach also provides an estimate of the (cluster-specific) relative risk (RR). 
Specifically, with 2m clusters (m assigned to intervention), the expected proportion of test-
positives in the intervention clusters is approximately 
𝑅𝑅
𝑅𝑅+(
𝑟
2
)(1+𝑅𝑅)
 , and 
1
1+(
𝑟
2
)(1+𝑅𝑅)
 for the 
control clusters, where the ratio of sampled controls to cases is r. For example, if r = 1 and 
RR = 0.5, the average proportion of test-positives in a treated cluster is 2/5 (0.40) and 4/7 
(0.57) in a control cluster. These calculations assume that the intervention effect is identical 
in all treated clusters. The difference in these average proportions of test-positives between 
intervention and control clusters yields an estimate of the relative risk since we can 
substitute the estimated difference in the proportions, d, into the formula 𝑑 =
1
1+(
𝑟
2
)(1+𝑅𝑅)
−
𝑅𝑅
𝑅𝑅+(
𝑟
2
)(1+𝑅𝑅)
, yielding a quadratic equation for RR. This yields an estimate of RR, along with 
an appropriately transformed confidence interval (from that for d) (41).  
Note that Generalized Estimating Equations estimates of the odds ratio that use robust 
variances do not perform well in situations where there are relatively few clusters. On the 
other hand, random effects logistic regression performs better and may provide a third 
alternative approach with sufficient clusters available (41).  
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(b) Individual-level analysis: In the CR-TND a form of ‘per-protocol’ analysis is 
likely of interest, to reduce the potential impact of exposure misclassification arising from 
the fact that some individuals in an intervention cluster may spend substantial time in a 
control cluster and vice-versa. This ‘contamination’ would necessarily reduce the observed 
effect of the intervention. Available measurements on such mobility contemporaneous to 
symptoms would then be included in an analysis that allows for individual-level covariates, 
in addition to calendar time as previously discussed.  
Modifications to the permutation distribution techniques used for either the odds ratio or 
the difference in average test-positive proportions across clusters, may be developed by 
extending similar approaches for standard cluster randomized trials (42-44). In addition, 
covariates can be introduced straightforwardly into a random effects logistic regression 
model. Incorporating calendar time in this way effectively fits a proportional hazards frailty 
model if one assumes that the intervention effect is constant over time.   
 
DISCUSSION 
Public health strategies to control dengue and other arboviruses lack a robust evidence base 
due to the absence of well-powered cluster randomized trials of community-level 
interventions with disease endpoints (2).  The absence of such trials might reflect the 
common belief that mosquito population suppression must inevitably lead to lower disease 
incidence, yet this relationship is poorly characterized and unlikely to be linear (45, 46).  
Additionally, there is a perception that cluster randomized trials require fever surveillance of 
pre-defined cohorts of ‘at risk’ individuals and that such efforts must always be logistically 
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and financially demanding. Here we propose that cluster randomized trials with test-
negative design sampling offer increased efficiency and validity by recruiting participants 
based on their outcome, rather than exposure status. Advantages include a smaller total 
sample size and potentially single rather than repeat contact with study participants, as well 
as avoidance of potential biases that can arise in longitudinal studies from under-
ascertainment of illness events or loss to follow-up. A primary advantage of the CR-TND 
approach over traditional TNDs is the randomization of the intervention that reduces 
confounding and provides a firm basis for inference. The CR-TND therefore represents an 
attractive novel design for trials of community-based interventions against acute infectious 
diseases such as dengue. 
The key assumption underlying the validity of CR-TND effect estimates is that the ratio of 
exposed to unexposed patients with test-negative illness is an unbiased estimate of the 
ratio of exposed to unexposed persons in the source population who would seek health care 
if they developed the test-negative (or test-positive) illness. This assumption could be 
violated if an inappropriate test-negative illness was selected, upon which the intervention 
has a true effect. For example, in the case of a dengue vector control intervention trial, 
another Aedes-borne pathogen such as Zika or chikungunya must be excluded from the 
classification of test-negative illness because the intervention could also feasibly modify the 
distribution of these diseases.  Furthermore, small numbers of clusters limit the power of 
the design. Our simulations indicate that constrained randomization may be useful to 
increase precision, particularly when the number of clusters under study is small. 
The outcome-based sampling in a CR-TND uses an odds ratio as the estimate of effect, the 
interpretation of which depends on the criteria applied in sampling test-negative controls. 
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When controls are sampled concurrently with cases and without regard for past or future 
test-positive illness, as is proposed here, the odds ratio of exposure in test-positive vs test-
negative patients yields a direct estimate of the relative risk in the source population. If the 
temporal matching of test-positives and test-negatives is accounted for in the analysis, then 
this becomes an unbiased estimate of the rate ratio , and thus the CR-TND can produce an 
equivalently intuitive and valid effect estimate as a traditional longitudinal CRT design but 
with potentially substantial savings in time and resources (41). 
In addition to its efficiency benefits, the outcome-based sampling employed in the CR-TND 
also has a potential advantage over traditional study designs in reducing biases that can 
arise through longitudinal follow-up where the ascertainment of disease endpoints relies on 
passive case detection of study participants presenting to clinics when ill. Such designs carry 
a risk of misclassification bias, as any cohort members with the disease of interest who fail 
to present to a study clinic, or to be identified upon presentation, are falsely classified as 
disease-free (21). Loss-to-follow up that is differential between study arms and/or outcome 
status is another potential source of bias in traditional longitudinal designs, particularly 
when follow-up periods are long. The health care-seeking behaviour of the population, if 
differential between treatment arms e.g. with a non-blinded intervention, can also 
confound the observed association between intervention and outcome (21). These biases 
are avoided in the CR-TND through the sampling of test-negative controls from the same 
patient population as the test-positive cases, and because of the random assignment of the 
intervention. CRTs of community interventions are susceptible to exposure misclassification 
if participants’ mobility patterns lead to contamination between intervention and control 
clusters. The CR-TND allows for inclusion of a per-protocol analysis employing more 
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nuanced exposure classification based on recall of movements just prior to illness onset, 
which would not be possible in e.g. a prospective serological cohort with sampling at annual 
or six-monthly intervals. 
A key challenge to implementation of the CR-TND, compared with an observational TND, is 
adaptation of analytical methods to account adequately for clustering of participants with 
respect to their intervention allocation status. We have elsewhere proposed methods to 
accommodate clustering in group-level analysis of intervention effect, using a permutation 
approach to statistical inference (41). Published CRT formulae for sample size calculations 
are inadequate for the CR-TND, and simulation studies based on baseline data, best 
estimates, or pilot studies are needed to assess the required sample size (41). Even for CRTs, 
sample size calculations need preliminary estimates of design effects induced by the 
clustering, information that is often poorly reported.  
Both the accuracy of sample size estimations, and the benefits conferred by constraining 
randomization to only those allocations in which balance is achieved in both test-negative 
and test-positive illness incidence, depend on the availability of reliable baseline data, and 
the degree to which historical patterns are likely to reflect the future illness distribution. The 
spatial and temporal variability in many infectious diseases, and their propensity to cluster 
in space and time, could lead to a different distribution being observed during the study 
period compared to baseline. The incidence rate ratio of test-negative illness between 
treated and untreated arms during the study period should therefore be reported; this 
should approximate one if the assumption of no relationship between intervention and test-
negative illness is upheld. Re-estimation of power/sample size at an interim time point after 
study commencement – using the trial data from the control arm to determine inter-cluster 
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heterogeneity of test-positive and test-negative illness – may also be advisable to affirm the 
estimates based on historical data. 
The study design described here extends the test-negative design to cluster-randomized 
intervention trials. We have demonstrated that valid estimates of effect are produced by 
the CR-TND, even with a relatively small number of clusters, particularly when constrained 
randomization is employed to ensure balance in baseline test-positive and test-negative 
illness, and assuming the core assumptions of the TND are upheld. This design offers 
potential for improving the efficiency of cluster randomized trials of preventive 
interventions, including for arboviral diseases such as dengue and Zika, through targeted 
clinic-based enrolment and testing of patients with a specified disease syndrome instead of 
longitudinal follow-up of large cohorts. Other public health applications in which the CR-TND 
could prove valuable include the evaluation of mass drug administration for parasitic 
infections, and estimation of both the direct and indirect (‘herd’) effects of vaccine-derived 
immunity in the context of vaccine trials or observational studies, subject to first 
establishing that the assumptions outlined here are upheld. 
Further extensions to this work will refine the approaches to statistical inference and 
sample size estimation, and develop methods for individual-level analysis that allow 
adjustment for individual covariates such as time of recruitment or non-binary exposure 
status due to mobility or heterogeneous coverage of the intervention. Extension to non-
parallel randomized allocations will also be explored, for example where a community-level 
intervention is deployed using a stepped-wedge design. The first field implementation of the 
CR-TND, to our knowledge, will be a cluster randomized controlled trial to assess the 
efficacy of Wolbachia-infected mosquito deployments against dengue in Yogyakarta, 
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Indonesia (ClinicalTrials.Gov #NCT03055585; (47)). This will provide a valuable opportunity 
to test both the feasibility and validity of the design in practice, generating learnings to 
inform improved design of trials to evaluate preventive interventions for vector-borne 
diseases and other public health priorities. 
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FIGURE LEGENDS 
Figure 1. Validity of odds ratio estimates from a simulated CR-TND study, under the null 
hypothesis of no intervention effect. Box and whiskers plots show the distribution of odds 
ratio estimates from 1000 simulated cluster-randomized allocations of a hypothetical 
dengue preventive intervention, displayed as the % deviation from the expected OR=1 
assuming that the true intervention efficacy is zero. The ten different scenarios within each 
graph represent a variable number of clusters under study (20 – 100) and two scenarios of 
the inter-cluster coefficient of variation (k) in baseline test-negative illness incidence: high 
(H; k=0.5) or low (L; k=0.25). Inter-cluster variation in baseline dengue incidence was 
constant in all scenarios (k=0.5). Random allocation of the intervention was either 
unconstrained (A), or constrained to ensure balance between the study arms (+/- 10%) in 
baseline dengue incidence (B), test-negative illness incidence (C), or both dengue and test-
negative illness incidence (D). Note that five OR estimates from Panel A (4/1000 simulations 
with 20 clusters & high k, and 1/1000 simulation with 20 clusters & low k) and two OR 
estimates in Panel C (2/1000 simulations with 20 clusters & low k) had a deviation value less 
than -150% and are not shown on the graph. 
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